MedTrace Logo

Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)

NCT00483106 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 885

Last updated 2021-03-16

No results posted yet for this study

Summary

Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem during childhood. It is estimated that up to 80% of this disorder could be related to genetic factors. The most common treatment for ADHD is psychostimulants. In this study, the researchers investigate the effect of genetic variants in increasing the risk for behaviours pertinent to ADHD or in modulating the response of these behaviours to methylphenidate. Response to methylphenidate is evaluated through a double blind placebo controlled one week study.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Ritalin

0.25 mg/kg bid, orally for 7 consecutive days

DRUG

Placebo

taken orally twice a day for 7 consecutive days

Sponsors & Collaborators

Principal Investigators

  • Ridha Joober, MD, PhD · Douglas Mental Health University Institute

  • Natalie Grizenko, MD, FRCPC · Douglas Mental Health University Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483106 on ClinicalTrials.gov